A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency.

Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y

European journal of endocrinology1 Jul 2007Cited by 78 (Europe PMC)

PMID17609397DOI10.1530/eje-07-0066PepBankPUB-17609397

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialActivity measurement
In healthy subjects and patients with low peak GH on insulin tolerance testing, serum GH peaked within 60 min after intravenous GHRP‑2 in all subjects.
In plain wordsIn healthy people and patients with low GH, growth hormone peaked within 60 minutes after a GHRP‑2 injection.
Peptide
GHRP-2
Outcome
Not applicableTime of serum GH peak after GHRP-2
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Measurements
Time to GH peak
≤ 60 min
all subjects
Source sentences
Summary
Serum GH peak occurred within 60 min after GHRP-2 administration in all subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939701
02HumanNon-randomized trialActivity measurement
GH responses to GHRP‑2 did not differ by gender.
In plain wordsGrowth hormone responses to GHRP‑2 were not affected by gender.
Peptide
GHRP-2
Outcome
No significant changeGH response to GHRP-2 by gender
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Source sentences
Summary
GH responses to GHRP-2 were not affected by gender, but were slightly lower in elderly subjects and those with adiposity, although these did not influence diagnosis of GHD.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939702
03HumanNon-randomized trialActivity measurement
GH responses to GHRP‑2 were slightly lower in elderly subjects, without an effect on the diagnosis of GHD.
In plain wordsElderly people had slightly lower growth hormone responses to GHRP‑2, but the diagnosis of GH deficiency was not changed.
Peptide
GHRP-2
Outcome
DecreaseGH response to GHRP-2 in elderly subjects
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Source sentences
Summary
GH responses to GHRP-2 were not affected by gender, but were slightly lower in elderly subjects and those with adiposity, although these did not influence diagnosis of GHD.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939703
04HumanNon-randomized trialActivity measurement
GH responses to GHRP‑2 were slightly lower in subjects with adiposity, without an effect on the diagnosis of GHD.
In plain wordsPeople with adiposity had slightly lower growth hormone responses to GHRP‑2, but the diagnosis of GH deficiency was not changed.
Peptide
GHRP-2
Outcome
DecreaseGH response to GHRP-2 in subjects with adiposity
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Source sentences
Summary
GH responses to GHRP-2 were not affected by gender, but were slightly lower in elderly subjects and those with adiposity, although these did not influence diagnosis of GHD.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939704
05HumanNon-randomized trialOther
Repeated GHRP‑2 tests showed favourable reproducibility.
In plain wordsRepeating the GHRP‑2 test gave consistent results.
Peptide
GHRP-2
Outcome
Not applicableReproducibility of the GHRP-2 test
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Source sentences
Summary
Repeated tests showed favourable reproducibility.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939705
06HumanNon-randomized trialEfficacy outcome
Peak GH after GHRP‑2 was lower in patients with GHD than in healthy subjects.
In plain wordsAfter GHRP‑2, patients with GH deficiency reached a much lower peak GH than healthy people.
Peptide
GHRP-2
Outcome
DecreasePeak GH after GHRP-2 in GHD patients versus healthy subjects
Study
n = 135
Comparator
Healthy subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Measurements
Peak GH
1.36 microg/l
patients
Peak GH
84.6 microg/l
healthy group
Source sentences
Summary
Peak GH concentrations after GHRP-2 were significantly (P<0.001) lower in patients (1.36+/-2.60 microg/l) than the healthy group (84.6+/-60.9 microg/l) with no difference between hypothalamic and pituitary diseases.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939706
07HumanNon-randomized trialActivity measurement
The GH concentration at which sensitivity and specificity of the GHRP‑2 test crossed ranged from 15 to 20 microg/l.
In plain wordsThe GH level where the GHRP‑2 test balanced catching deficiency and avoiding false alarms was 15 to 20 microg/l.
Peptide
GHRP-2
Outcome
Not applicableGH level at the crossing of sensitivity and specificity
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Measurements
GH at sensitivity-specificity crossing
15 to 20 microg/l
GHRP-2 test
Source sentences
Summary
Serum GH concentration at the point where sensitivity of response crossed with specificity ranged from 15 to 20 microg/l.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939708
08HumanNon-randomized trialActivity measurement
A GHRP‑2 cut-off of 15 microg/l corresponded to the diagnostic ITT value of 3 microg/l for GHD.
In plain wordsA peak GH of 15 microg/l after GHRP‑2 matched the 3 microg/l cut-off of the standard insulin tolerance test.
Peptide
GHRP-2
Outcome
Not applicableGHRP-2 cut-off equivalent to the ITT cut-off
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Measurements
GH cut-off
15 microg/l
GHRP-2 test
GH cut-off
3 microg/l
ITT
Source sentences
Summary
A cut-off value of 15 microg/l for diagnosing GHD with GHRP-2 corresponded to the diagnostic value of 3 microg/l in the ITT.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939709
09HumanNon-randomized trialActivity measurement
With GH calibrated to the recombinant WHO 98/574 standard, the GHRP‑2 cut-off for severe GHD was 9 microg/l instead of 15 microg/l.
In plain wordsWith a different GH calibration standard, the cut-off for severe GH deficiency after GHRP‑2 was 9 microg/l instead of 15.
Peptide
GHRP-2
Outcome
Not applicableGHRP-2 cut-off after GH assay calibration
Study
n = 135
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Measurements
GH cut-off
15 microg/l
GHRP-2 test
GH cut-off
9 microg/l
calibrated with WHO 98/574
Source sentences
Summary
using a 15 microg/l (9 microg/l when GH calibrated with recombinant World Health Organization 98/574 standard) cut-off for peak GH concentration
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939710
10HumanNon-randomized trialActivity measurement
Peak GH after GHRP‑2 did not differ between patients with hypothalamic and pituitary diseases.
In plain wordsPeak GH after GHRP‑2 was similar in patients with hypothalamic and pituitary disease.
Peptide
GHRP-2
Outcome
No significant changePeak GH after GHRP-2 in hypothalamic versus pituitary disease
Study
n = 58
Comparator
Pituitary disease
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · intravenousAs given in this study (human).
Source sentences
Summary
with no difference between hypothalamic and pituitary diseases.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled.
Summary · context
After overnight fasting, a 100 microg dose of GHRP-2 was administered intravenously; blood samples were taken during the subsequent 2 h and GH measured by immunoradiometric assay.
Report a problemFND-1760939707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.